[HTML][HTML] Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease

S De Iudicibus, R Franca, S Martelossi… - World journal of …, 2011 - ncbi.nlm.nih.gov
Natural and synthetic glucocorticoids (GCs) are widely employed in a number of
inflammatory, autoimmune and neoplastic diseases, and, despite the introduction of novel …

Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis

O Teuffel, SP Kuster, SP Hunger, V Conter, J Hitzler… - Leukemia, 2011 - nature.com
This systematic review and meta-analysis compared the efficacy and toxicity of
dexamethasone (DEX) versus prednisone (PRED) for induction therapy in childhood acute …

[HTML][HTML] Pharmacogenomic and pharmacotranscriptomic profiling of childhood acute lymphoblastic leukemia: paving the way to personalized treatment

S Pavlovic, N Kotur, B Stankovic, B Zukic, V Gasic… - Genes, 2019 - mdpi.com
Personalized medicine is focused on research disciplines which contribute to the
individualization of therapy, like pharmacogenomics and pharmacotranscriptomics. Acute …

[HTML][HTML] Epigenetic modifications and glucocorticoid sensitivity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

WC de Vega, S Herrera, SD Vernon… - BMC medical genomics, 2017 - Springer
Abstract Background Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a
debilitating idiopathic disease characterized by unexplained fatigue that fails to resolve with …

Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy

L Mei, EP Ontiveros, EA Griffiths, JE Thompson… - Blood reviews, 2015 - Elsevier
Acute lymphoblastic leukemia (ALL) is a relatively rare disease in adults accounting for no
more than 20% of all cases of acute leukemia. By contrast with the pediatric population, in …

Pharmacogenetics of childhood acute lymphoblastic leukemia

E Lopez-Lopez, A Gutierrez-Camino… - …, 2014 - Taylor & Francis
Acute lymphoblastic leukemia (ALL) is the major pediatric cancer in developed countries.
Although treatment outcome has improved owing to advances in chemotherapy, there is still …

Genetic variation in the glucocorticoid pathway involved in interindividual differences in the glucocorticoid treatment

QQ Song, WY Xie, YJ Tang, J Zhang, J Liu - Pharmacogenomics, 2017 - Taylor & Francis
Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic
syndrome, acute lymphoblastic leukemia and other autoimmune diseases. However, in a …

[PDF][PDF] Association between N363S and BclI polymorphisms of the glucocorticoid receptor gene (NR3C1) and glucocorticoid side effects during childhood acute …

MK Cihan, HG Karabulut, NY Kutlay… - Turkish Journal of …, 2017 - jag.journalagent.com
Objective: Glucocorticoids (GCs) are the key drugs for the treatment of pediatric acute
lymphoblastic leukemia (ALL). Herein, investigation of the relationship between the N363S …

Implementation of pharmacogenetics to individualize treatment regimens for children with acute lymphoblastic leukemia

D Maamari, H El-Khoury, O Saifi… - Pharmacogenomics …, 2020 - Taylor & Francis
Despite major advances in the management and high cure rates of childhood acute
lymphoblastic leukemia (ALL), patients still suffer from many drug-induced toxicities …

Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol

R Franca, P Rebora, N Bertorello, F Fagioli… - The …, 2017 - nature.com
Drug-related toxicities represent an important clinical concern in chemotherapy, genetic
variants could help tailoring treatment to patient. A pharmacogenetic multicentric study was …